Hyperinsulinemia supposedly contributes to hypertension in diabetes mellitus. We sought to determine if the renal and cardiovascular effects of insulin are preserved in diabetes despite resistance to its glucose-lowering effect We studied the effects of two doses of insulin (50 and 500 miliiunits/kg • hr~'), using the euglycemic clamp technique, on fractional sodium excretion, blood pressure, and heart rate in two groups of non-insulin-dependent diabetics: eight patients with and eight patients without hypertension. Hypertensive diabetics had higher basal insulin levels than normotensive diabetics (21.8±2.9 and 14.4±1.6 milliunjts/l, respectively [mean±SEM]; p=0.03). The degree of insulin resistance, but not plasma insulin levels, correlated with the height of mean arterial blood pressure (r=0.60 and 0.73 at the low and high insulin dose, respectively, p< 0.05). In contrast, the change in mean arterial blood pressure correlated negatively with the change in endogenous insulin levels during the control experiment (r=-0.41, /7<0.02). Exogenous insulin induced a similar reduction in fractional sodium excretion in normotensive and hypertensive diabetics (43 ±5.9% and 48±16.4% during the low insulin dose and 57±9.1% and 62±12.5% during the high insulin dose, respectively). A decline in blood pressure was noted that correlated with the whole body glucose uptake during the high insulin dose (r=0.52, p< 0.05). Since heart rate response and plasma norepinephrine level during the insulin clamp were comparable in both groups, an abnormality of the baroreceptor reflex is suggested. It appears that insulin resistance, but not insulin, is primarily related to hypertension. At the same time, insulin may still exert some effect on blood pressure by way of its renal or vasodilatory, or both, action. (Hypertension 1992^0:199-209) KEY WORDS • insulin resistance • sympathetic nervous system • sodium • renin-angiotensin system R ecent studies have suggested that hyperinsulinemia, insulin resistance, or both, may be the common denominator underlying the blood pressure elevation in essential hypertension, obesity, and non-insulin-dependent diabetes mellitus (NIDDM). 1 -3 Ferrannini et al 4 have demonstrated, by using the euglycemic clamp technique, that patients with untreated essential hypertension and a still-normal glucose tolerance (according to World Health Organization (WHO) criteria) were insulin resistant compared with normotensive control subjects. The severity of hypertension correlated with the degree of insulin resistance as determined by the glucose infusion rates to maintain euglycemia. A positive relation between basal plasma insulin levels and height of the blood pressure has also been described in a group of nondiabetic subjects, of which the majority revealed blood pressure levels within the normal range.
sion. 7 Also, NIDDM patients with hypertension appear to have higher fasting insulin levels and to be more insulin resistant than their normotensive counterparts. 8 ' 9 Although a causal relation between hyperinsulinemia and hypertension is still to be established, insulin may contribute to an increase in blood pressure through several mechanisms. An increase in plasma insulin level within or slightly above the physiological range markedly reduces fractional sodium excretion. 10 - 12 During comparable levels of hyperinsulinemia, an increase in the cardiovascular reactivity to norepinephrine but not angiotensin II has been found. 13 Insulin may also exert a direct positive inotropic and chronotropic effect on the heart, 1415 although this is not generally accepted. 16 With higher levels of plasma insulin, a dose-dependent increase in sympathetic nervous system (SNS) activity has been observed, 17 although we could not substantiate these findings. 12 Participation of the renin-angiotensinaldosterone system (RAAS), as has been suggested at an earlier stage, 12 -18 has been ruled out by a proper inhibition study. 19 It is clear that if one assumes a causal role for insulin in the pathogenesis of hypertension in NIDDM, sensitivity to at least some of the possible blood pressureelevating actions of insulin should be preserved in this condition despite resistance to the glucose-lowering action of the hormone. 20 Preliminary evidence suggests that this may be the case indeed. NIDDM patients appear to be equally sensitive to the sodium-retaining action of insulin as are age-and body weight-matched control subjects without diabetes. 21 It is yet unknown whether this also holds true for the other possible blood pressure-elevating actions of insulin and if there exist differences between NIDDM patients with and without hypertension regarding this aspect of insulin action. To further elucidate these issues, we have compared, using the eugrycemic clamp technique, the renal and cardiovascular effects of two doses of insulin in two groups of patients with NIDDM: one group with and one group without hypertension but matched for other confounding variables.
Methods

Patients
Two groups of patients with NIDDM were recruited from the outpatient diabetic clinic. The first group consisted of eight patients with NIDDM and hypertension, matched for age, sex, and body mass index to a second group of eight patients with NIDDM but no hypertension. NIDDM was defined according to the WHO criteria. 22 Metabolic control was judged to be satisfactory when fasting plasma glucose levels were less than 8.5 mmol/1 and, thus, no glucosuria could be demonstrated. Except for one patient in the normotensive group, who was treated with diet only, all patients used oral hypogrycemic agents. Hypertension was defined as a diastolic blood pressure above 95 mm Hg on at least two occasions during a 4-week washout period preceding the experiments (i.e., after all antihypertensive medication had been withdrawn). Secondary forms of hypertension had been excluded by standard procedures. All subjects had normal liver, kidney (normal serum creatinine, albustix negative), and thyroid function. Exclusion criteria were a history of angina, myocardial infarction, heart failure, cerebrovascular accident, intermittent claudication, an abnormal electrocardiography, and an untreated blood pressure exceeding 180/110 mm Hg, or the presence of diabetic complications, i.e., retinopathy other than a "background" retinopathy, nephropathy, and neuropathy. The latter was defined absent if routine neurological evaluation did not yield abnormal results. Informed consent was obtained from all subjects, and the study was approved by the Ethical Committee of the Free University Hospital.
Protocol
In all NIDDM patients with hypertension, antihypertensive medication was withdrawn 4 weeks preceding the experiment. Blood pressure was measured at weekly intervals, and the patient was excluded from the study if blood pressure rose above 180/110 mm Hg or failed to rise above the preset diastolic value of 95 mm Hg on the last two occasions. For all patients dietary habits were kept unchanged. However, if 24-hour urinary sodium excretion, measured twice in the 4-week run-in period, did not exceed 150 mmol per day, the extra amount of sodium necessary to reach this level was supplied with capsules containing 500 mg NaCl; compliance was confirmed by measuring the 24-hour urinary sodium excretion again. Oral hypogrycemic agents were continued until the day of the experiment.
Eugfycemic Hyperinsulinemic Clamp Experiment
After an overnight fast, all subjects came to the outpatient clinic at 8 AM. After a basal period of 2 hours (Bas), a 4-hour euglycemic hyperinsulinemic clamp was performed with two increasing doses of insulin for 2 hours each, according to previously described methods.
12
- 23 That day all oral hypogrycemic agents had been omitted. During the first 2 hours, insulin (Humulin S, Lilly, Indianapolis, Ind., diluted to 40 ml with Haemaccel, Hoechst, Amsterdam, Holland) was infused at a rate of 50 milliunits/kg • hr" 1 (Ins I), after a priming dose had been given. During the last 2 hours of the clamp experiment, the rate of infusion was increased to 500 milliunits/kg • hr" 1 (Ins II), again after a priming dose had been given. The insulin level established during the lowest insulin infusion rate is within the physiological range. The highest rate induced a supraphysiological degree of hyperinsulinemia, but it is at these levels that a systemic pressor effect of insulin has been noted. 12 -17 At the beginning of the experiment and each following hour, all subjects drank 300 ml tap water to ensure sufficient diuresis. Every 30 minutes they were asked to empty their bladder. During the whole duration of the study, all subjects were in a supine position, except when voiding. Systolic and diastolic blood pressure and heart rate were measured every 10 minutes with a semicontinuous blood pressure measuring device (Nippon Colin BP 103 N Sphygmomanometer, Hayashi, Komaki-city, Japan).
Control Experiment
On separate days and within 1 week after the insulinclamp experiment had been performed, the control experiment was carried out in an identical fashion, with infusion of the same amount of insulin solvent and with blood sampling at the same time intervals, including blood sampling for blood glucose measurements. To correct for any (nonspecific) change in sodium excretion or change in blood pressure, heart rate, or both, due to volume expansion as the result of dextrose 20% infusion to maintain eugrycemia, 24 -25 a corresponding amount of water was given orally each half hour. Absorption of water from the gastrointestinal tract is rapid and complete, so that no relevant lag in volume expansion was to be expected when compared with intravenous dextrose 20% administration. Control experiments had to be performed after the insulin clamp experiments because we could not determine beforehand the amount of dextrose 20% to be infused each hour. Control experiments enabled us to correct for any circadian variation in the variables under evaluation.
Blood samples for measurement of the various substances were drawn twice during the second hour of each 2-hour period (Bas, Ins I, and Ins II). Urine and serum concentrations of sodium, potassium, creatinine, and glucose were determined by standard laboratory methods. Plasma renin activity and plasma aldosterone levels were determined by radioimmunoassay. Plasma insulin concentrations were measured by radioimmunoassay, using Insik 5 from Sorin Biomedia, Saluggia, Italy (intra-assay variation 2-4%). Plasma catecholamines (norepinephrine and epinephrine) were determined by high-performance liquid chromatography (HPLC) with electrochemical detection. 26 HbAlc was determined by HPLC (normal range, 4.3-6.1%; intra-assay variation, 2.6%).
Fractional sodium excretion (FeNa) was calculated as (urinary sodium x plasma creatinine plasma sodium x urinary creatinine) xl00%
FeNa was preferred to absolute sodium excretion rate, because it corrects for changes in glomerular filtration rate as well as dead space or incomplete voiding. Pulse pressure was calculated as the difference between systolic and diastolic blood pressure, and mean arterial blood pressure as diastolic blood pressure plus one third of pulse pressure. The double product, a noninvasive correlate of myocardial oxygen consumption, 27 was calculated by multiplying heart rate and systolic blood pressure.
A quantitative estimate of insulin sensitivity was provided by the mean glucose infusion rate in the second hour of the euglycemic clamp and was expressed as M value. The latter represents glucose metabolized during steady state with corrections for changes in glucose pool. 28 The ratio M/I, where I is insulin, is a measure of the quantity of glucose metabolized per unit of plasma insulin concentration. By correcting for differences in steady-state plasma insulin levels, M/I is a better index for comparison of possible changes or differences in tissue sensitivity to insulin. 29 For convenience M/I ratio was multiplied by 100.
Statistical Analysis
All results regard the first (A) and last (B) 30 minutes of the second hour of each 2-hour period (Bas, Ins I, and Ins II). To avoid bias caused by circadian variation of the variables under evaluation, the measurements during the control experiments were subtracted from the corresponding measurements obtained during the clamp experiment before statistical analysis was performed. For each variable separately, the adjusted measurements were analyzed by the method of analysis of variance (ANOVA) for repeated measurements for differences between periods A and B, for differences between normotensive and hypertensive NIDDM patients, and to determine whether there existed a dosedependent effect of the administered insulin. In addition, two-sided 95% confidence intervals for the difference in average effect between normotensive and hypertensive NIDDM were calculated. Twenty-fourhour urinary sodium excretion rates, fasting glucose levels, plasma insulin levels, M values and M/I ratios, HbAlc, and patient characteristics (including body mass index and age) were analyzed using the two sample t test and Fisher's exact test. Correlation and linear regression analysis were applied when appropriate. Partial correlation coefficients denote correlation coefficients corrected for differences in body mass index and age. A value of p<0.05 was considered significant. Data are reported as mean±SEM, unless stated otherwise.
Results
Patient characteristics are given in Table 1 . NIDDM patients with and without hypertension were comparable with respect to age, sex, body mass index, duration of diabetes, and metabolic control as measured by HbAlc and fasting glucose levels. Fasting plasma insulin levels were significantly higher in the hypertensive NIDDM patients. The average urinary sodium excretion rate per day did not differ between the two groups, and none of the patients needed extra amounts of sodium chloride.
Clamp characteristics and insulin sensitivity variables are provided in Table 2 . In both groups plasma insulin levels during the insulin clamp experiment showed a dose-dependent increase over basal values, the increase in plasma insulin levels being consistently higher in hypertensive NIDDM compared with normotensive NIDDM. In each group basal plasma insulin levels on the day of the insulin clamp experiment did not differ from basal values on the control day. However, fasting insulin levels fell gradually thereafter in both groups (Table 2) . Mean blood glucose level during the insulin clamp experiment and the coefficients of variation of the glucose levels were comparable between the two groups. Mean blood glucose levels during the control experiment were also not different from those during the insulin clamp experiment. Hypertensive NIDDM patients were more insulin resistant than their normotensive counterparts, regardless of whether this was expressed as the M value or as the M/I value. When the data from both groups of patients were taken together, negative correlations were observed between the heights of systolic, diastolic, and mean arterial blood pressure, and the insulin sensitivity expressed as M value or M/I value at either of the two insulin levels (Ins I, Ins II; see Table 3 and Figure 1 ). No correlation between blood pressure height and basal plasma insulin levels could be discerned (Figure 2A ). In contrast, the change in fasting insulin levels during the day of the control experiment did correlate negatively with the change in mean arterial pressure measured at the same time points ( Figure 2B ). The effects of insulin on FeNa and cardiovascular variables are shown in Table 4 and Figure 3 . There were no significant differences for any of these variables between period A and period B of the second hour of each 2-hour period, i.e., Bas, Ins I, and Ins II. Exogenous insulin led to a dose-dependent decrease in FeNa in both groups. The degree of this reduction in FeNa did not, however, differ between normotensive and hypertensive NIDDM patients (percentage reduction in normotensive NIDDM, Ins I and Ins II, 43±5.9% and 57±9.1%, respectively; hypertensive NIDDM, Ins I and Ins II, 48±16.4% and 62±12.5%). The absence of glucose in the urine had been con- firmed for all urine samples. Notably, no correlation between the change in fasting insulin level and change in FeNa during the control experiment was found (r=-0.1,p=0.6).
In both groups a dose-dependent decline in systolic, diastolic, and mean arterial blood pressure was noted. Interestingly, the change in diastolic blood pressure in both groups at the highest insulin infusion rate was found to correlate with whole body glucose uptake (M value) at this insulin level (see Figure 4) . This implies that the more insulin resistant the patient was, the greater the decline in diastolic blood pressure that occurred during the highest insulin infusion rate. Heart rate increased dose-dependenth/ during insulin administration, but again the increase was not found to differ between the groups. Pulse pressure did not change in either of the two groups (data not shown). In contrast to the normotensive group, in which no changes were observed (data not shown), the double product tended to decline in the hypertensive group (insulin clamp, The effects of increasing doses of insulin on plasma catecholamines, plasma renin activity, plasma aldosterone, and serum potassium are presented in Table 5 . There were no statistically significant differences for any of these variables between period A and period B of the second hour of each 2-hour period, i.e., Bas, Ins I, and Ins II. During insulin administration a dose-dependent increase in plasma norepinephrine levels occurred. However, the change in plasma norepinephrine levels did not differ between normotensive and hypertensive NIDDM patients. There was no change in plasma epinephrine levels in any of the groups. Divergent effects on plasma renin activity and aldosterone levels were noted. Plasma renin activity showed an increase, whereas aldosterone levels did not change or tended to decrease (p=0.08). Interestingly, these effects appeared to be more marked in the hypertensive compared with the normotensive NIDDM patients. Finally, insulin led to a dose-dependent decline in serum potassium, which was of a comparable magnitude in both groups. Discussion This study confirms the notion that NIDDM patients with hypertension have higher plasma insulin levels and are more insulin resistant than their normotensive counterparts. 8 -9 Similar to results obtained in patients with untreated essential hypertension, the severity of hypertension closely correlated with the degree of insulin resistance. 4 However, no such relation between blood pressure height and the plasma insulin levels could be discerned. In contrast, the change in endogenously circulating insulin correlated negatively with the change in mean arterial blood pressure during the day. In line with this observation, a decline in blood pressure was noted during insulin infusion that appeared to be most marked in patients with NIDDM and hypertension. At the same time, insulin induced a comparable degree of sodium retention in both groups of NIDDM, regardless of whether hypertension was present.
Studies concerning the action of insulin at sites that are supposedly involved in the blood pressure regulation of NIDDM patients are scarce. Compared with nondiabetic controls, NEDDM patients demonstrated an unaltered sodium-retaining effect. 21 Although our present study lacks a nondiabetic control group, the magnitude of change in sodium excretion was comparable to that observed in a previous study performed in healthy volunteers. 12 An unaltered renal action of insulin despite the presence of resistance to the glucoselowering action of the hormone, is supported by the observation that the (renal) peritubular uptake of insulin, which is supposedly related to its sodium-retaining action, is unaltered in NIDDM patients compared with nondiabetic controls. 30 As expected, the peripheral insulin extraction was significantly impaired in the diabetic patients. 30 Whether the sodium retaining action of insulin is also preserved in other insulin resistant states, e.g., patients with essential hypertension or obesity, cannot yet be answered. Although at the whole body level all three conditions are characterized by a diminished glucose uptake, important differences emerge when insulin action is studied at the tissue level. 4 Unfortunately, in patients with essential hypertension no information is available at all. In obesity conflicting results have been reported. A decrease in sodium excretion not different from that observed in lean control subjects was noted in one study, 31 whereas no change, and even a paradoxical increase, was noted in two others. 32 -33 One restriction should, however, be made. Although there appears to be a dissociation between the blood glucose-lowering effect of insulin and its renal action in NIDDM, it cannot be excluded that we are merely looking at a hypokalemia-related reduction in urinary sodium excretion. One group of investigators has recently shown that the sodium-retaining effect of insulin can be abolished when the occurrence of hypokalemia is prevented by concomitant infusion of potassium chloride. 34 However, this particular study lacks a control study with infusion of potassium chloride alone. Exogenous potassium has been shown by the same group to exert a specific natriuretic effect. 35 Since NIDDM patients with hypertension had higher basal insulin levels than NIDDM patients without hypertension, our data support the notion that insulin may contribute to blood pressure height in NIDDM by way of its sodium-retaining action. However, for several reasons we believe that the actual contribution of insulin to blood pressure height through this mechanism is only minimal at the most. In a previous study in healthy volunteers we noted that the maximal sodiumretaining effect of insulin was offset at an increase in systolic blood pressure of only 18 mm Hg. 12 The difference in insulin levels between hypertensive and normotensive NIDDM is approximately one tenth of the rise in insulin levels needed to induce maximal sodium retention in that study. Since the renal effects of insulin are dose-dependent, 11 it is clear that insulin can only explain a very small part of the blood pressure difference between hypertensive and normotensive diabetics. The lack of a correlation between the change in insulin levels and the change in FeNa during the control experiment supports this conclusion. Furthermore, although an increase in exchangeable body sodium is a regular finding in NIDDM, the rise in body sodium does not correlate with the prevailing blood pressure and can already be discerned in normotensive diabetics. 36 - 37 One study in dogs also suggests that insulin-induced sodium retention does not lead to an elevated blood pressure. 38 Although insulin infusion for 28 days initially caused sodium retention, it was followed by a "renal escape" associated with an increase in glomerular filtration rate and no changes in blood pressure or heart rate. In the few patients in whom the occurrence of so-called "insulin-edema" has been described, an elevation of the blood pressure was also not one of the features. 39 The effect of exogenous insulin on blood pressure is an intriguing observation. It has recently been shown that insulin stimulates muscle blood flow in a dosedependent fashion. 40 A nonspecific vasodilation or capillary recruitment, or both, as a consequence of the increase in tissue metabolism, i.e., glucose oxidation, is the most likely mechanism. 14 - 40 In accordance, acute increases in plasma insulin within the physiological range have been shown to produce a decrease in forearm vascular resistance and a slight decline in diastolic blood pressure in normal subjects. 41 At supraphysiological degrees of hyperinsulinemia, however, an increase in systolic blood pressure has been demonstrated by several groups. 12 - 17 Assuming that insulin does not affect arterial compliance, the latter is most likely related to a direct positive inotropic and chronotropic effect of insulin. 19 -42 Few studies have addressed the cardiovascular effects of insulin in insulin-resistant patients. There is compelling evidence, however, that in both obesity and diabetes mellitus, the vasodilatory response to insulin is diminished, although it can be overcome by increasing the insulin dose sufficiently.
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' 44 The finding of a negative correlation between the change in mean arterial blood pressure and the change in fasting insulin level during the control experiment suggests, however, that changes in endogenous circulating insulin may already affect blood pressure height in diabetes. Still, one would have expected that any blood pressure decline to occur by this vasodilatory action of insulin would have been the least in the patients that were the most insulin resistant, i.e., the hypertensive NTDDM. In contrast, the decline in blood pressure in our present study correlated negatively with whole body glucose uptake at the highest insulin infusion rate and, thus, appeared to be most marked in the hypertensive patients. At the same time, similar changes in heart rate and plasma norepinephrine level as indexes of sympathetic tone were observed in both All results are the average of the first (A) and last (B) 30 minutes of the second hour of each period. Bas, basal values; Ins I, 50 milliunits insulin/kg-hr~' or vehicle only in case of control experiment; Ins II, 500 milliunits insulin/kg • hr~' or vehicle only in case of control experiment; ANOVA, analysis of variance; p It normotensive vs. hypertensive patients; pi, Ins I and Ins II vs. Bas (to test for a dose-dependent effect); FeNa, fractional sodium excretion; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; HR, heart rate.
*Two-sided 95% confidence intervals for difference in average effect between normotensive and hypertensive patients.
groups. Assuming a normal baroreceptor reflex arch, a greater increase in these variables would have been expected in the hypertensive patients that showed the greatest decline in blood pressure. In contrast, the more insulin resistant the patients were, the less the cardiac response was to counteract the vasodilatory effect of increased glucose metabolism. This notion is supported by the fact that the double product, and thus myocardial oxygen consumption, tended to decline in the hypertensive NIDDM (/?=0.07) but not in the normotensive NIDDM patients. A pronounced decrease in blood pressure after insulin administration has been reported earlier, but this appeared to be related to the presence of autonomic neuropathy. 13 - 43 Although it was not excluded by specific tests, none of our patients had clinical evidence of (autonomic) neuropathy. Whether insulin affects the baroreceptor reflex is uncertain. One study in diabetics could not disclose any alteration, 46 whereas another, performed in normal volunteers and neuropathic patients, suggested a blunting of the baroreceptor reflex after oral carbohydrate administration. 47 Alternatively, the lack of a difference in the cardiac response between the two groups may reflect the presence of a cardiomyopathy. Both in insulin-dependent diabetes as well as NIDDM, a diminished left ventricular function has been documented, which may be attributed to the state of insulin resistance. 48 - From the foregoing it is obvious that we view the observed increase in plasma norepinephrine levels as a compensatory one, albeit not of a sufficient magnitude, to counteract the fall in blood pressure. In contrast to Rowe et al, 17 we have not been able to document a change in plasma norepinephrine levels during comparable levels of hyperinsulinemia in our group of normal subjects that showed an increase in systolic blood pressure during a euglycemic clamp. 12 The rise in plasma renin activity and the decline in aldosterone levels are most likely related to the insulin-induced decrease in serum potassium concentration, since in another study no changes occurred when the fall in serum potassium concentration was prevented. 18 It is not clear why these changes were more marked in our hypertensive NIDDM patients despite comparable decreases in serum potassium concentrations.
The absence of an association between basal plasma insulin level and blood pressure height, in contrast to insulin resistance, points to the fact that insulin resistance rather than insulin itself is primarily related to hypertension. At first sight insulin levels are the mirror image of insulin resistance. However, the prevailing insulin levels are not only determined by the degree of resistance to the glucose-lowering effect of this hormone, but also by the metabolic clearance rate and the secretory capacity of /J-cells. The more abnormal the last factor is, as is undoubtedly the case in NIDDM, the less likely the height of the insulin level will reflect the degree of insulin resistance indeed. It follows that by the same token a relation between insulin and blood pressure will fade, if insulin itself is not primarily related to the hypertensive state. Decreased metabolic clearance rate also readily explains the fact that the attained insulin levels in our hypertensive patients clearly exceeded those in the normotensive group, despite identical infusion rates. Metabolic clearance rate of insulin has been shown to decrease with declining insulin sensitivity. 50 Notably, the difference in basal insulin levels between hypertensive and normotensive NIDDM patients has been ascribed to a decreased (hepatic) insulin extraction. 8 In contrast, the major part of insulin resistance in hypertensive NIDDM patients, at least in the nonobese, resides at •Two-sided 95% confidence intervals for difference in average effect between normotensive and hypertensive patients.
the peripheral tissues, i.e., the muscles, 9 that represent peripheral vascular resistance at the same time.
The question of whether insulin resistance itself is causally related to hypertension associated with NIDDM or other insulin-resistant states cannot be answered. Several observations are in favor of such an assumption. It has long been known that interventions such as weight reduction, exercise, and, more recently, treatment with metformin, reduce blood pressure, 51 -53 at the same time increasing insulin sensitivity. Experimental evidence indicates that changes at the cellular level, involving calcium ion dynamics, may be responsible for the occurrence of insulin resistance as well as the increased contractile state of vascular smooth muscle cells that characterizes at least some forms of hypertension. 54 Also, the possibility has been raised that both insulin resistance and hypertension are the result of microvascular dysfunction. 55 Both arteriolar rarefaction 56 as well as a decreased vasodilatory capacity 57 -58 may contribute to the rise in peripheral vascular resistance, and at the same time, hamper capillary exchange resulting in insulin resistance.
In conclusion, our results suggest that insulin resistance is primarily related to the pathogenesis of an elevated blood pressure associated with NIDDM. At the same time, insulin may still exert some effect on blood pressure height by way of its renal or vasodilatory, or both, action. 
